Akeem Yusuf

机构：Texas Tech University, Amgen (United States), Texas Tech University Health Sciences Center · ORCID：0000-0002-0001-1311

发表论文 61 篇 · 总被引 1678 次 · h-index 14

代表论文

• Predictors of imminent risk of fracture in Medicare-enrolled men and women (2020 · Archives of Osteoporosis · 被引 31)
• Evaluation of claims‐based computable phenotypes to identify heart failure patients with preserved ejection fraction (2020 · Pharmacology Research & Perspectives · 被引 26)
• Bemarituzumab plus mFOLFOX6 as first-line treatment in East Asian patients with FGFR2b-overexpressing locally advanced or metastatic gastric/gastroesophageal junction cancer: subgroup of FIGHT final analysis (2024 · Gastric Cancer · 被引 14)
• Characteristics of migraine patients with Migraine Disability Assessment (MIDAS) scores in real-world clinical practice (2020 · Cephalalgia Reports · 被引 10)
• Carfilzomib 56 mg/m 2 twice-weekly in combination with dexamethasone and daratumumab (KdD) versus daratumumab in combination with bortezomib and dexamethasone (DVd): a matching-adjusted indirect treatment comparison (2022 · Leukemia & lymphoma/Leukemia and lymphoma · 被引 5)
• P-191: Comparison of efficacy outcomes for Carfilzomib plus Dexamethasone and Daratumumab (KdD) versus Pomalidomide plus Bortezomib and Dexamethasone (PVd) and D-Pd in relapsed or refractory Multiple Myeloma (2021 · Clinical Lymphoma Myeloma & Leukemia · 被引 4)